Johnson & Johnson to Acquire Abiomed for ~$16.6B
Shots:
- J&J to acquire all outstanding shares of Abiomed for an up front of $380.00/share representing a 50.7% premium over its closing price of $252.08 at an enterprise value of ~ $16.6B. Abiomed shareholders will receive a non-tradeable CVR of ~$35.00/share upon milestones achievement & the transaction is expected to be close in Q1’23
- The milestones fees incl. $17.50/share, if net sales for Abiomed products exceed ~$3.7B at J&J’s fiscal Q2’27 through fiscal Q1’28, $7.50/share upon FDA premarket application approval of Impella products, $10.00/share in 1st publication of a Class I recommendation for Impella products
- The acquisition expands JJMT’s portfolio with a leading platform in HF, SoC, market opportunity through a robust pipeline of technologies & clinical studies, near & long-term sales, and earnings growth
Ref: Johnson & Johnson | Image: Pfizer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
